AR035805A1 - Compuestos de dihidropirimidina ciano sustituidos - Google Patents
Compuestos de dihidropirimidina ciano sustituidosInfo
- Publication number
- AR035805A1 AR035805A1 ARP020101175A ARP020101175A AR035805A1 AR 035805 A1 AR035805 A1 AR 035805A1 AR P020101175 A ARP020101175 A AR P020101175A AR P020101175 A ARP020101175 A AR P020101175A AR 035805 A1 AR035805 A1 AR 035805A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- group
- compounds
- heteroarylalkyl
- arylalkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oncology (AREA)
- Urology & Nephrology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Communicable Diseases (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Molecular Biology (AREA)
- Rheumatology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Psychology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
Abstract
Compuestos de la fórmula (1) sus enantiómeros, diastereómeros, sales farmacéuticamente aceptables, prodrogas y solvatos del mismo, donde R1 está seleccionado del grupo que consiste en hidrógeno, alquilo y cicloalquilo; Y1, Y2, Y3, Y4 e Y5 están independientemente seleccionados del grupo que consiste en H, halógeno, alquilo inferior, O alquilo, O arilo, NH alquilo, NH arilo, N alquilalquilo, N alquilarilo, N arilarilo con la condición de que al menos uno de Y1, Y2, Y3, Y4 e Y5 sea arilo o heteroarilo; R4 está seleccionado del grupo que consiste en alquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo, heterocicloalquilalquilo, CN, COR5, CO2R5 y CONR5R6; R5 y R6 están independientemente seleccionados del grupo que consiste en H, alquilo, haloalquilo, cicloalquilo, aminoalquilo, arilalquilo, cicloalquilalquilo, heteroarilalquilo y heterocicloalquilalquilo; Z está seleccionado del grupo que consiste en O, S y NR8; R8 está seleccionado del grupo que consiste en H, CN, sulfonamido, OR7, alquilo, cicloalquilo, arilo, arilalquilo, heterociclilo, heteroarilo y heteroarilalquilo; y R7 está seleccionado del grupo que consiste en H, alquilo, arilalquilo, cicloalquilalquilo, heterocicloalquilalquilo y heteroarilalquilo. Los compuestos de fórmula (1) inducen al paro mitótico y por ello son útiles como agentes anticancerígenos y para el tratamiento de otras enfermedades que pueden ser tratadas induciendo el paro mitótico.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US27995601P | 2001-03-29 | 2001-03-29 | |
US10/104,382 US6900214B2 (en) | 2001-03-29 | 2002-03-22 | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
AR035805A1 true AR035805A1 (es) | 2004-07-14 |
Family
ID=26801480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP020101175A AR035805A1 (es) | 2001-03-29 | 2002-04-02 | Compuestos de dihidropirimidina ciano sustituidos |
Country Status (24)
Country | Link |
---|---|
US (1) | US6900214B2 (es) |
EP (1) | EP1373223A4 (es) |
JP (1) | JP2004529139A (es) |
KR (1) | KR20030086328A (es) |
CN (1) | CN1500082A (es) |
AR (1) | AR035805A1 (es) |
BG (1) | BG108195A (es) |
BR (1) | BR0208353A (es) |
CA (1) | CA2442484A1 (es) |
CZ (1) | CZ20032643A3 (es) |
EE (1) | EE200300473A (es) |
HR (1) | HRP20030874A2 (es) |
HU (1) | HUP0400341A3 (es) |
IL (1) | IL157442A0 (es) |
IS (1) | IS6966A (es) |
MX (1) | MXPA03008635A (es) |
NO (1) | NO20034301L (es) |
NZ (1) | NZ527617A (es) |
PE (1) | PE20020997A1 (es) |
PL (1) | PL364005A1 (es) |
RU (1) | RU2003131975A (es) |
SK (1) | SK11072003A3 (es) |
WO (1) | WO2002079169A1 (es) |
YU (1) | YU75603A (es) |
Families Citing this family (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999001124A1 (en) | 1996-12-03 | 1999-01-14 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
US6809102B2 (en) | 2001-03-29 | 2004-10-26 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
PT1847534E (pt) * | 2001-12-11 | 2011-08-01 | Kyowa Hakko Kirin Co Ltd | Derivado de tiadiozolina para o tratamento do cancro |
US7649006B2 (en) | 2002-08-23 | 2010-01-19 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto and analogues thereof |
WO2004018478A2 (en) | 2002-08-23 | 2004-03-04 | Sloan-Kettering Institute For Cancer Research | Synthesis of epothilones, intermediates thereto, analogues and uses thereof |
CN101787000B (zh) | 2003-04-18 | 2011-08-03 | 协和发酵麒麟株式会社 | M期驱动蛋白抑制剂 |
KR20060014071A (ko) * | 2003-06-10 | 2006-02-14 | 교와 핫꼬 고교 가부시끼가이샤 | 티아디아졸린 유도체 |
US7157461B2 (en) | 2003-07-23 | 2007-01-02 | Bristol-Myers Squibb Co. | Substituted dihydropyrimidine inhibitors of calcium channel function |
US7166603B2 (en) | 2003-07-23 | 2007-01-23 | Bristol-Myers Squibb Co. | Dihydropyrimidone inhibitors of calcium channel function |
WO2005037799A1 (en) * | 2003-10-16 | 2005-04-28 | Cytokinetics, Inc. | Compounds, compositions, and methods |
KR20070046176A (ko) | 2004-08-18 | 2007-05-02 | 아스트라제네카 아베 | 특정 융합 피리미돈의 거울상이성질체 및 이의 암 치료 및예방에 있어서의 용도 |
FR2883284A1 (fr) * | 2005-03-15 | 2006-09-22 | Commissariat Energie Atomique | Nouveaux derives dihydropyrimidines et leur utilisation comme agents anti-cancereux |
CA2602397A1 (en) * | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | Therapeutic agent for solid tumor |
WO2006101103A1 (ja) * | 2005-03-22 | 2006-09-28 | Kyowa Hakko Kogyo Co., Ltd. | 造血器腫瘍治療剤 |
US7910611B2 (en) * | 2005-06-24 | 2011-03-22 | Kyowa Hakko Kirin Co., Ltd. | Therapeutic agent for restenosis |
DE102006002065B4 (de) * | 2006-01-16 | 2007-11-29 | Infineon Technologies Austria Ag | Kompensationsbauelement mit reduziertem und einstellbarem Einschaltwiderstand |
EP2455456A1 (en) | 2010-11-22 | 2012-05-23 | Institut Curie | Use of kinesin inhibitors in HIV infection treatment and a method for screening them |
AU2012300274B2 (en) * | 2011-08-26 | 2017-06-29 | Sanford-Burnham Medical Research Institute | HIV replication inhibitors |
CN105237465B (zh) * | 2015-11-13 | 2017-07-21 | 吉林大学 | 一种具有神经保护作用的化合物及医用用途 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS422265Y1 (es) | 1965-10-21 | 1967-02-10 | ||
US6211198B1 (en) * | 1993-04-05 | 2001-04-03 | Synaptic Pharmaceutical Corporation | Dihydropyridines and new uses thereof |
PL320263A1 (en) | 1994-11-16 | 1997-09-15 | Synaptic Pharma Corp | Dihydropyrimidines and their application |
WO1997017969A1 (en) | 1995-11-16 | 1997-05-22 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
JP2000506904A (ja) | 1996-05-16 | 2000-06-06 | シナプティック・ファーマスーティカル・コーポレーション | ジヒドロピリミジン類およびその使用 |
US6172066B1 (en) * | 1996-05-16 | 2001-01-09 | Synaptic Pharmaceutical Corporation | Dihydropyrimidines and uses thereof |
CA2294349A1 (en) | 1997-06-18 | 1998-12-23 | Michael A. Patane | Alpha 1aadrenergic receptor antagonists |
US6080760A (en) * | 1997-06-18 | 2000-06-27 | Merck & Co., Inc. | Alpha 1A adrenergic receptor antagonists |
AU1403099A (en) | 1997-11-14 | 1999-06-07 | Merck & Co., Inc. | Alpha-1a adrenergic receptor antagonists |
WO1999050440A2 (en) | 1998-04-01 | 1999-10-07 | Yale University | Method to identify modulators of survivin - tubulin interaction |
US6300084B1 (en) | 1998-10-08 | 2001-10-09 | The Regents Of The University Of California | Anti-mitotic agent screening process |
GB9914258D0 (en) * | 1999-06-18 | 1999-08-18 | Celltech Therapeutics Ltd | Chemical compounds |
AUPQ171999A0 (en) | 1999-07-20 | 1999-08-12 | University Of Sydney, The | Neurotropic virus transport |
DE19935303A1 (de) | 1999-07-28 | 2001-02-08 | Aventis Pharma Gmbh | Oligonukleotide zur Inhibierung der Expression von humanem eg5 |
US6617115B1 (en) | 1999-10-27 | 2003-09-09 | Cytokinetics, Inc. | Methods of screening for modulators of cell proliferation |
MXPA02004162A (es) | 1999-10-27 | 2003-08-20 | Cytokinetics Inc | Metodo y composiciones que utilizan quinazolinonas. |
US6284480B1 (en) * | 2000-04-03 | 2001-09-04 | Cytokinetics, Inc. | Antifungal assay |
US6809102B2 (en) * | 2001-03-29 | 2004-10-26 | Bristol-Myers Squibb Company | Cyano-substituted dihydropyrimidine compounds and their use to treat diseases |
-
2002
- 2002-03-22 US US10/104,382 patent/US6900214B2/en not_active Expired - Lifetime
- 2002-03-26 RU RU2003131975/04A patent/RU2003131975A/ru not_active Application Discontinuation
- 2002-03-26 BR BR0208353-1A patent/BR0208353A/pt not_active IP Right Cessation
- 2002-03-26 IL IL15744202A patent/IL157442A0/xx unknown
- 2002-03-26 EP EP02731175A patent/EP1373223A4/en not_active Withdrawn
- 2002-03-26 EE EEP200300473A patent/EE200300473A/xx unknown
- 2002-03-26 NZ NZ527617A patent/NZ527617A/en unknown
- 2002-03-26 SK SK1107-2003A patent/SK11072003A3/sk unknown
- 2002-03-26 YU YU75603A patent/YU75603A/sh unknown
- 2002-03-26 CN CNA028074564A patent/CN1500082A/zh active Pending
- 2002-03-26 CA CA002442484A patent/CA2442484A1/en not_active Abandoned
- 2002-03-26 JP JP2002577796A patent/JP2004529139A/ja not_active Withdrawn
- 2002-03-26 CZ CZ20032643A patent/CZ20032643A3/cs unknown
- 2002-03-26 WO PCT/US2002/009494 patent/WO2002079169A1/en not_active Application Discontinuation
- 2002-03-26 HU HU0400341A patent/HUP0400341A3/hu unknown
- 2002-03-26 PL PL02364005A patent/PL364005A1/xx not_active Application Discontinuation
- 2002-03-26 MX MXPA03008635A patent/MXPA03008635A/es unknown
- 2002-03-26 KR KR10-2003-7012607A patent/KR20030086328A/ko not_active Application Discontinuation
- 2002-04-01 PE PE2002000257A patent/PE20020997A1/es not_active Application Discontinuation
- 2002-04-02 AR ARP020101175A patent/AR035805A1/es unknown
-
2003
- 2003-09-24 IS IS6966A patent/IS6966A/is unknown
- 2003-09-24 BG BG108195A patent/BG108195A/bg unknown
- 2003-09-26 NO NO20034301A patent/NO20034301L/no not_active Application Discontinuation
- 2003-10-28 HR HR20030874A patent/HRP20030874A2/xx not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
IS6966A (is) | 2003-09-24 |
PL364005A1 (en) | 2004-11-29 |
KR20030086328A (ko) | 2003-11-07 |
US20020143026A1 (en) | 2002-10-03 |
BR0208353A (pt) | 2004-03-23 |
HRP20030874A2 (en) | 2004-04-30 |
PE20020997A1 (es) | 2002-11-08 |
WO2002079169A8 (en) | 2004-04-29 |
CZ20032643A3 (en) | 2004-06-16 |
HUP0400341A2 (hu) | 2004-10-28 |
WO2002079169A1 (en) | 2002-10-10 |
EE200300473A (et) | 2004-02-16 |
IL157442A0 (en) | 2004-03-28 |
RU2003131975A (ru) | 2005-05-10 |
US6900214B2 (en) | 2005-05-31 |
JP2004529139A (ja) | 2004-09-24 |
MXPA03008635A (es) | 2004-02-23 |
EP1373223A4 (en) | 2004-09-29 |
EP1373223A1 (en) | 2004-01-02 |
CN1500082A (zh) | 2004-05-26 |
NZ527617A (en) | 2005-02-25 |
BG108195A (bg) | 2004-07-30 |
NO20034301L (no) | 2003-11-10 |
NO20034301D0 (no) | 2003-09-26 |
SK11072003A3 (sk) | 2004-06-08 |
CA2442484A1 (en) | 2002-10-10 |
HUP0400341A3 (en) | 2004-11-29 |
YU75603A (sh) | 2006-05-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR035805A1 (es) | Compuestos de dihidropirimidina ciano sustituidos | |
AR034585A1 (es) | Nuevos compuestos de dihidropirimidina ciano substituidos y su uso para tratar padecimientos | |
CA2532818A1 (en) | (thio) carbamoyl-cyclohexane derivatives as d3/d2 receptor antagonists | |
AR037907A1 (es) | Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6 | |
AP1753A (en) | Thiophene derivatives as antiviral agents for flavvivirus infection | |
AR048820A1 (es) | Tiadiazolidinonas como inhibidores de la glucogeno sintasa quinasa-3(gsk-3) | |
PE20021002A1 (es) | Compuestos heterociclicos condensados | |
CO5601018A2 (es) | Derivados de n-fenil-2-pirimidin-amina | |
CR7846A (es) | Derivados de 3-aminopirrolidina como moduladores de receptores de quimocina | |
PE20070041A1 (es) | Amidas de acido pirazolcarboxilico | |
PE20040600A1 (es) | Derivados de triazol como antagonistas del receptor de taquicinina | |
ECSP066415A (es) | 2-carbonilamino-6-piperidinaminopiridinas sustituidas y 1-carbonilamino-3-piperidinaminobenzenos sustituidos como 5-ht1f agonistas | |
CO5601020A2 (es) | Compuestos ox-azabiciclicos | |
AR043700A1 (es) | Derivados de 3-substituida-4-pirimidona | |
AR053340A1 (es) | Derivados de trifluormetilbenzamida y sus usos terapeuticos | |
AR047958A1 (es) | Derivados de 1-bencil-5-piperazin-1-il-3,4 dihidro-1h-quinazolin-2-ona y sus derivados 1h-benzo(1,2,6)tiadiazina-2,2-dioxidos y 1,4-dihidro-benzo(d)(1,3)oxazinas-2-ona,como moduladores del receptor 5-ht,para el tratamiento de enfermedades del sistema nervioso central. | |
GT200900172A (es) | Acetofenonas sustituidas utiles en terapia. | |
ES2113422T3 (es) | Agentes herbicidas que contienen 2-aminotiofenos substituidos. | |
EA200500598A1 (ru) | Бифункциональные фенилизо(тио)цианаты, способ и промежуточные продукты для их получения | |
ES2111580T3 (es) | 3-(piridinilamino)-indoles y benzo(b)tiofenos sustituidos, un procedimiento para su preparacion y su uso como medicamentos. | |
AR036812A1 (es) | Inhibidores de la 17beta-hidroxiesteroide deshidrogenasa tipo 3, composiciones farmaceuticas y el uso de dichos compuestos para la fabricacion de medicamentos para el tratamiento de enfermedades androgeno-dependientes | |
PL301611A1 (en) | Anti-retroviral hydrazine derivatives | |
CO4600635A1 (es) | Procedimientos e intermedios para preparar derivados de cromanol sustituidos | |
ECSP045200A (es) | Acidos 3-(imidazolil)-2-alcoxipropanoicos | |
AR019438A1 (es) | Compuesto derivado de piperazina, usos del mismo y metodos para su fabricacion |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |